Gabapentin Capsule
Product Images NDC 68788-8489

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8489). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules 100mg (E3429322 C442 4146 Bb68 Bcc3a8d01552 00)

The packaging label for Gabapentin Capsules 100 mg from Preferred Pharmaceuticals Inc. displays the drug name and strength prominently, noting it as a generic for Neurontin. The label includes storage instructions, manufacturer information (ScieGen Pharmaceuticals, Inc), and warnings. Dosage directions are provided in both English and Spanish on a yellow background, along with barcode and QR code elements. The label also has placeholders for quantity, lot, batch, and product NDC numbers.*

FDA Label Image

Figure 1 (Image 01)

A line graph comparing mean pain scores over an 8-week period between a placebo group and a group taking Gabapentin 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decrease in pain scores over time, while placebo scores remain relatively steady.*

FDA Label Image

Figure 2 (Image 02)

Line graph comparing mean pain scores over a 7-week period among placebo and two Gabapentin treatment groups at 1800 mg/day and 2400 mg/day. The graph includes phases for a 3-week dose titration period followed by a 4-week fixed dose period, showing a decline in mean pain scores for both Gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

Bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies. The y-axis represents the proportion of responders as a percentage from 0% to 100%. Study 1 compares placebo (PBO) at 12% and Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo (PBO) at 14%, GBP 1800 mg at 32%, and GBP 2400 mg at 34%. Statistical significance is indicated by ** (p < 0.01) and *** (p < 0.001).*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A mathematical formula calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a gender adjustment factor for females.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin, showing its molecular arrangement with a cyclohexane ring bonded to an amino group and a carboxyl group.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing percentage difference on the y-axis and daily dose in milligrams on the x-axis. The plot compares data points from three different studies labeled as study a, study b, and study c, using distinct symbols for each. Data points range from 600 mg to 1800 mg daily dose with percentage differences from about 5% to 20%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.